Organon investigates Prometrium reports as Quebec regulator clarifies replacement rules
Organon says a Prometrium investigation is ongoing and no recall is in force. Quebec’s pharmacy regulator says free replacement is not mandatory without a recall.
In this article & details
Organon says it is investigating reports concerning Prometrium progesterone capsules, while Quebec’s pharmacy regulator has clarified that pharmacists are not required to replace the medicine without charge when no recall has been issued.
The manufacturer and the Ordre des pharmaciens du Québec issued separate statements on November 13, following public concerns about suspected lack of effectiveness. Organon’s statement says the investigation is continuing and no special measure, including a recall, is currently in force.
Patients sought refunds after media coverage
The Ordre’s notice says patients contacted it after pharmacists declined to take back and refund capsules that the patients believed were ineffective. It referred to recent La Presse reporting about concerns involving certain lots.
The regulator said a Health Canada recall is the trigger for return and replacement in such circumstances. Without one, pharmacists do not have an obligation to provide a free replacement. That position addresses replacement arrangements; the notice does not establish that a product defect has been confirmed.
The Ordre asks people taking either Prometrium or generic progesterone to report unusual adverse effects to Health Canada. It says possible options can be discussed with a pharmacist, including an early refill, contacting the prescriber or changing from the original brand to a generic when appropriate and not contraindicated.
Manufacturer says reports have been shared with Health Canada
In its statement, Organon says it records, assesses and investigates adverse-event reports and product-quality complaints, and has communicated the reports to Health Canada under applicable requirements. It says Prometrium continues to be manufactured to regulatory and quality standards and that patients may continue using it according to the product monograph.
Organon describes the medicine’s indication as an addition to postmenopausal estrogen replacement therapy for women with a uterus, to substantially reduce the risk of endometrial hyperplasia and resulting carcinoma.
The company reiterates the labelled handling directions: capsules are taken orally and swallowed whole, without chewing, crushing, puncturing or opening them. They should be protected from light and stored between 15°C and 30°C.
The two November 13 statements describe an unresolved investigation and the arrangements available while no recall is in effect. Neither announces a confirmed affected-lot list or a new recall.
References
- Mise au point concernant le Prometrium® — Ordre des pharmaciens du Québec, November 13, 2026
- Mise à jour sur PROMETRIUM® (progestérone) — Organon Canada, November 13, 2026